Back to Results

Evaluation of Upadacitinib for Vitiligo


A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Non-Segmental Vitiligo

Therapeutic Area Vitiligo
Principal Investigator David Rosmarin, MD
Min Age 18 Years
Max Age 65 Years
Gender Any
Contact Nicole Dumont
More Information


The primary objective of this study is to evaluate the safety and efficacy of upadacitinib for the treatment of adult subjects with NSV.

Study Details

Inclusion Criteria

  • Clinical diagnosis of active or stable vitiligo made by a dermatologist
  • Stop all other treatments for vitiligo from screening through the final follow up visit

Exclusion Criteria

  • Subjects must not have previously been treated with any topical or systemic JAK inhibitor
  • Use of biologic or investigational therapy or procedure within 12 weeks prior to Visit 0

Study Requirements

Study is expected to last up to 14 months. This includes a 35-day screening period, a 24-week double blind treatment period (Period 1), a 28-week blinded long-term extension (Period 2), and a 30-day follow-up period.